Premium
Low‐dose oral chloroquine in the treatment of porphyria cutanea tarda
Author(s) -
ASHTON R.E.,
HAWK J.L.M.,
MAGNUS I.A.
Publication year - 1984
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1984.tb06632.x
Subject(s) - dermatology , medicine , porphyria cutanea tarda
SUMMARY Seven patients with porphyria cutanea tarda received a total of ten courses of low‐dose oral chloroquine therapy (125 mg chloroquine phosphate twice weekly). Patients were treated for a mean 14.9 months during which time all went into clinical and biochemical remission. Relapse occurred in four patients on a total of six occasions after a mean 17 months. In four patients there was no relapse after a mean 47·3 months. There were no adverse side‐effects from the treatment. Low‐dose oral chloroquine therapy appears to be a safe, effective and convenient treatment for porphyria cutanea tarda, although relapses may occur requiring further therapy.